M&A / Deals UK’s Claret Capital raises 575m for European biotechs PharmaphorumLondon-based Claret Capital Partners has closed its fourth European Growth Capital Fund, raising 575m for "Europe's boldest innovators."Read full story pharminent September 7, 2026 (Last updated: September 7, 2026) Pharmaphorum London-based Claret Capital Partners has closed its fourth European Growth Capital Fund, raising 575m for “Europe’s boldest innovators.” Read full story Post navigation Previous: Major trial of Roche Alzheimer’s drug kicks off in EuropeNext: Novartis and Ionis’ Pelacarsen Lowers Lp(a) but Misses on Cardiovascular Outcomes Related Stories M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026 M&A / Deals Boehringer signs AI drug discovery deal with Owkin pharminent September 3, 2026 M&A / Deals Novartis signs $3.2bn drug delivery deal with Alteogen pharminent September 3, 2026